Loxo Unveils More Data, Paves a Path Forward In Precision Oncology

 An experimental cancer drug from Loxo Oncology has shown early signs that it might impact multiple tumor types, regardless of where in the body they originated. The clinical results come with caveats, but they add to a slowly growing body of evidence supporting so-called tumor “agnostic” drugs, which are markers for the progress of precision cancer medicines. Loxo could later this year become only the second company to have such a drug on the market.